Prescribing information is available by clicking the links at the bottom of the page

<h2>Recording</h2>
Length: 15:49

TYPE-2-DIABETES

DIABETES

Paradigm 2024:
Lesley Mills

Get in touch with the Diabetes Team

<table border="1" cellpadding="1" cellspacing="1" style="width:500px;">
 <tbody>
 <tr>
 <td>
 <a href="${link:{uuid:{8cd02cf2-bd72-495f-b720-698ef8d3f0da},repository:{dam},path:{/Portal/UK/Prescribing-links/Toujeo.pdf}}}" target="_blank">Prescribing Information UK</a> 
 &nbsp;</td>
 </tr>
 </tbody>
</table>

<table border="1" cellpadding="1" cellspacing="1" style="width:500px;">
 <tbody>
 <tr>
 <td>
 <a href="${link:{uuid:{acd7760d-f31d-4d7e-8b21-2cdf496d1cc2},repository:{dam},path:{/Portal/UK/Prescribing-links/Lantus_GB_NI.pdf}}}">Prescribing Information&nbsp;UK</a> 
 &nbsp;</td>
 </tr>
 </tbody>
</table>

<h2>Recording</h2>
Length: 22:21

Paradigm 2024:
Anne Goodchild

Ketan Dhatariya&nbsp;&nbsp;

<h2>Recording</h2>
Length: 27:14

Paradigm 2024:
Saqib Mahmud

<h2>Recording</h2>
Length: 17:19

Paradigm 2024:
Ketan Dhatariya 

Prescribing information is available by clicking the links at the bottom of the page
<h4>Catch up on Sanofi's sponsored symposium at the HEART UK conference 2024. See the presentation slides below on 'The patients journey to their LDL-C goal', presented by Dr Adie Viljoen and Dr Mohamed Elnaggar</h4>

<h2>The patients journey to their LDL-C goal</h2>

<h2>Practical guidance on helping your patient reach goal</h2>

DYSLIPIDEMIA

CARDIOLOGY

Get in touch with the Dyslipidaemia Team

<table border="1" cellpadding="1" cellspacing="1" style="width:500px;">
 <tbody>
 <tr>
 <td>
 <a href="${link:{uuid:{55f30477-c7e2-49c0-8cfc-16966f28d4c2},repository:{dam},path:{/Portal/UK/Prescribing-links/praluent-gb-pi.pdf}}}" target="_blank">Prescribing Information(GB) </a> <a href="${link:{uuid:{9e0d6f97-2ebb-4422-92ab-569b89c7dfe0},repository:{dam},path:{/Portal/UK/Prescribing-links/Praluent-PI-NI.pdf}}}" target="_blank">Prescribing Information(NI)</a></td>
 </tr>
 </tbody>
</table>

HEART UK

<h2 class="contentBlock__subtitle text-title-3 text- font-title block">Introduction</h2>
At Sanofi, we offer a selection of training options for healthcare professionals. These include live meetings which you can register to attend or, alternatively, watch on demand at a time that suits you. We also have non-promotional disease training available through the Lumiere site.

Online and face-to-face promotional educational meetings for HCPs
We provide various opportunities for you to join your peers and learn more about our areas of vaccine expertise both in-person and online.
This includes promotional educational meetings and training programmes which allow you to network with and learn from expert speakers on a range of topics, such as influenza, paediatric and travel disease, vaccination updates and vaccination best practice workshops.&nbsp;
We also offer vaccine-specific training for pharmacists and nurses, including face-to-face flu vaccination training and online training. Additionally, we provide seasonal influenza vaccination training courses for individuals interested in further developing their flu vaccination skills.
Our events calendar is regularly updated. If you are interested in staying up-to-date and finding out more about our upcoming events and meetings, please complete our&nbsp;<a href="/uk/articles/contact-vaccines">online contact form</a>.

A non-promotional medical education programme developed for healthcare professionals
Lumiere is designed to build on your existing skills and knowledge to help you protect your patients against vaccine-preventable diseases – from immunology basics to practical consultation skills.
<a href="https://www.sanofivaccines.co.uk/lumiere?utm_source=Campus&amp;utm_medium=website&amp;utm_campaign=web-link" target="_blank">Visit Lumiere</a>

OTHER-VACCINES-TOPICS

VACCINES

Vaccines Education and Training

Rezurock▼ (Belumosudil) is intended for HCPs practising in Great Britain (England, Scotland and Wales) only.

TRANSPLANT

In these roundtable discussions, patient case studies are discussed from countries (UK and Spain) to illustrate country-specific differences in the chronic GvHD treatment paradigm, including the use of Rezurock.
<h3>Management of chronic GvHD</h3>

EBMT 2024: Expert Exchange: Exploring the clinical practicalities of managing GvHD

This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.

Download ROCKstar study summary. This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only​

Get in touch with the Transplant Team

Abbreviations

<h3>Expanding the treatment paradigm with novel therapeutics</h3>

EBMT 2024: Expanding the cGvHD treatment paradigm with novel therapeutics

Length: 10mins
This video introduces novel therapies for chronic GvHD treatment, an overview of the MOAs, and an overiew of the key data from complete clinical trials.

Download ROCKstar study summary. This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only​.

<h3>Advances in the biology of chronic GvHD</h3>

EBMT 2024: Advances in the biology of chronic GvHD

Length: 15mins
In this video, Professor Ernst Holler provides an overview with insights into how the pathophysiology and biology of chronic GvHD has evolved over the past decade. He discusses the sequence of events that lead to autoreactivity following transplantation, including the role of B-cells and antibody production. Holler also highlights the remaining gaps in our understanding, including risk factors and biomarker identification.

To read this content, please activate your Sanofi Campus account via the email we've sent to you.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

title

In order to see relevant content, tell us what you are interested in

Title

Create new password

complete your profile to help us provide you with content that's relevant to you.

Your profile is incomplete

Development of ADCT involved literature review as well as interviews with patients and physicians, and was funded by Sanofi and Regeneron.

The ADCT gives a measure of how controlled your patient’s eczema is. Use these 6 concise questions to evaluate all dimensions of atopic dermatitis control.

Atopic dermatitis, a type of eczema, may be affecting your patient’s life in more ways than you know.

Enjoy more exclusive content{newline}by <a>registering today</a>

MAT-XU-2300297 (v3.0) - Date of preparation: October 2023

MAT-XU-2305062 (v1.0) - Date of preparation: November 2023

MAT-XU-2300297 (v3.0) Date of Preparation: October 2023

MAT-XU-2305047 (v1.0) - Date of preparation: November 2023

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

This website is for healthcare professionals only.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

The page you are looking for may be under maintenance, or the link may be incorrect.

Sorry, we can't find this page

You are going to a website that is not operated by Sanofi or a Sanofi website where the terms of use may differ. For external websites, Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party or Sanofi sites.

You are now leaving the Sanofi campus UK website

You are about to leave Campus.sanofi/uk.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch.

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your QFITLIA Representative or receive updates about QFITLIA. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

This site is intended for UK healthcare professionals only and contains information on Sanofi UK's medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a UK healthcare professional. This site contains promotional information. Please note that some of the content on the website is only relevant for HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

MAT-XU-2300297 (v6.0) - Date of Preparation: April 2024

Welcome to Sanofi Campus UK

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privary matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My Consent

{resultsCount, plural, one {result} other {results}}

Please sign in to access to the results

You need to sign-in to your account in order to access medical content.

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

Latest Education

Paradigm 2024: Lesley Mills

Paradigm 2024: Anne Goodchild

Paradigm 2024: Saqib Mahmud

Paradigm 2024: Ketan Dhatariya

HEART UK

Vaccines Education and Training

EBMT 2024: Expert Exchange: Exploring the clinical practicalities of managing GvHD

EBMT 2024: Expanding the cGvHD treatment paradigm with novel therapeutics

EBMT 2024: Advances in the biology of chronic GvHD